Promising activity for late-stage patients with relapses/refractory multiple myeloma
BestPractice | Jun 2019 | | EHA 2019
Despite recent advances in MM therapy, the disease remains incurable. Patients with late-stage RRMM refractory to pomalidomide and/or daratumumab have limited effective treatment options. Melflufen is a novel peptide-conjugated alkylator potentiated by intracellular aminopeptidases, which are markedly overexpressed in multiple myeloma. In this MEDtalk Paul G. Richardson present updated efficacy and safety of melflufen + low-dose dexamethasone in patients refractory to pomalidomide and/or daratumumab (HORIZON-study).